-+ 0.00%
-+ 0.00%
-+ 0.00%

Alterity Therapeutics appoints Ann Cunningham to board as independent director

PUBT·04/17/2026 10:05:16
Listen to the news
Alterity Therapeutics appoints Ann Cunningham to board as independent director
  • Alterity Therapeutics appointed Ann Cunningham to board as independent non-executive director, effective April 17, 2026.
  • Cunningham is founder and CEO of i³ Strategy Partners, a pharmaceutical consulting group focused on patient engagement strategies.
  • Her prior senior roles include Eli Lilly, Teva Pharmaceuticals, and Otsuka America; she currently serves on board of Vistagen Therapeutics and previously served as its chief commercial officer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-012602), on April 17, 2026, and is solely responsible for the information contained therein.